Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 30; pp. v327 - v328
Main Authors Abida, W., Campbell, D., Patnaik, A., Sautois, B., Shapiro, J., Vogelzang, N.J., Bryce, A.H., McDermott, R., Ricci, F., Rowe, J., Zhang, J., Simmons, A.D., Despain, D., Dowson, M., Golsorkhi, T., Chowdhury, S.
Format Journal Article
LanguageEnglish
Published 01.10.2019
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1093/annonc/mdz248.003